Physician profile
Stephanie Phan Le
NPI 1407190093
$5,037.82
in general payments reported to CMS, 2019-2025
20 companies · $664 in 2025
The $664 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $145 · 2021: $893 · 2022: $701 · 2023: $1,265 · 2024: $612 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,057.84 | 2019-2025 | Vemlidy |
| Amarin Pharma, INC. | $619.66 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.90 | 2021-2025 | Jardiance |
| Amgen INC. | $446.53 | 2022-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $418.56 | 2020-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $400.15 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $214.32 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $212.74 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Lilly USA, LLC | $189.27 | 2023-2025 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $164.81 | 2023-2025 | Bexsero, Arexvy |
| Edwards Lifesciences Corporation | $135.64 | 2022 | |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Alkermes, INC. | $117.19 | 2023 | Lybalvi |
| Inspire Medical Systems, INC. | $99.22 | 2023 | Inspire |
| Nestle Healthcare Nutrition INC. | $96.39 | 2021-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $84.78 | 2022-2023 | Slynd |
| Scilex Pharmaceuticals INC. | $57.62 | 2022-2023 | Ztlido |
| Abbvie INC. | $36.92 | 2020-2021 | |
| Ibsa Pharma INC. | $16.50 | 2024 | Licart, Tirosint |
| Sanofi Pasteur INC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.